Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic AML Group – LD-VenEx
2020-005461-14Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Rigshospitalet. Primary endpoint: Complete remission (CR). Started May 2021; status: active.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2020-005461-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005461-14.